Evaluation of the current legislation and guidance documents applied to bioassays in clinical trials: a case study to prove the vaccines immunogenicity
DOI:
https://doi.org/10.22239/2317-269X.00734Keywords:
Bioassays, Quality Control, Vaccines, Official Compendia, Current LegislationAbstract
Vaccines are immunobiologicals products considered safe, effective and essential to control and / or eradication of vaccine-preventable diseases, and they were submitted to analytical tests and bioassays to check the quality and therapeutic efficacy. In this study was evaluated the applicability of the Executive Director Resolution of the National Health Surveillance Agency, (Anvisa), RDC nº 27 May 17, 2012 and analyzed the other standardized bioassays documents recommended to the World Health Organization, Food and Drug Administration, United States Pharmacopeia, European Medicines Agency and data literature. The analyses of data literature and regulation statutes showed inconsistent guidelines. This study showed that is essential create a more targeted legislation to respond the particularities of bioanalytical assays in clinical trials to ascertain the vaccines immunogenicity. In order to corroborate with this guideline elaboration was carried out a case study by a standardized measles virus plaque reduction neutralization test in a 96-well plates (Micro-PRNT) to measure vaccinia neutralization according to RDC nº 27 May 17, 2012, 27 focus on the effectiveness of tests that is used in vaccine generated immune responses studies. The results showed that the method provides the selectivity and specificity required for applicability in combination vaccines as MMR (mumps, measles and rubella) or MMRV (measles, mumps, rubella and varicella vaccine).Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Health Surveillance under Debate: Society, Science & Technology (Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnología) – “Visa em Debate”

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
COPYRIGHT ALLOWANCE The author (s) hereinafter designated as the ASSIGNOR hereby assign and transfer, free of charge, the ownership of the copyrights related to this ARTICLE to the Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia (Health Surveillance under Debate: Society, Science & Technology) – Visa em Debate, represented by FUNDAÇÃO OSWALDO CRUZ, established at Av. Brasil, nº 4365, Manguinhos, Rio de Janeiro, RJ, Brazil, CEP 21045-900, under the conditions set out below: (a) The terms and conditions set forth in this Agreement shall apply to the following: 1. The ASSIGNOR declares that they s(he) is (are) the author (s) and owner (s) of the copyrighted property of the ARTICLE submitted. 2. The ASSIGNOR declares that the ARTICLE does not infringe the copyrights and / or other property rights of third parties, that the disclosure of images (if any) has been authorized and that they s(he) assume(s) full moral and / or property liability for its content, before third parties. 3. THE ASSIGNOR assigns and transfers all copyrights relating to the ARTICLE to the ASSIGNEE, especially the rights of editing, publication, translation into another language and reproduction by any process or technique. The ASSIGNEE becomes the exclusive owner of the rights related to the ARTICLE, and any reproduction, totally or partially, is prohibited in any other means of publicity, printed or electronic, without prior written authorization from the ASSIGNEE. 4. The assignment is free and, therefore, there will be no remuneration for the use of the ARTICLE by the ASSIGNEE.